How do synthetic calcitonin formulations primarily help patients with osteoporosis?

• A. By promoting bone resorption
• B. By inhibiting bone resorption
• C. By stimulating osteoblast activity
• D. By enhancing calcium absorption

Answer: (B)

Synthetic calcitonin formulations are primarily beneficial for patients with osteoporosis because they inhibit bone resorption. Calcitonin, a hormone produced by the thyroid gland, works by binding to specific receptors on osteoclasts, the cells responsible for breaking down bone. When calcitonin binds to these receptors, it decreases the activity and number of osteoclasts, leading to a reduction in bone resorption.

This action helps to maintain or increase bone density, which is crucial for individuals with osteoporosis, a condition characterized by weakened bones and an increased risk of fractures. By targeting the cellular processes involved in bone metabolism, synthetic calcitonin effectively helps to protect against the progression of osteoporosis and decrease the likelihood of bone-related complications.

The other options do not pertain to the primary action of synthetic calcitonin in osteoporosis management. Since calcitonin does not promote bone resorption, stimulate osteoblast activity, or enhance calcium absorption directly, they do not reflect the hormonal mechanism by which calcitonin operates in relation to osteoporosis treatment.